Maternal Serum Vascular Endothelial Growth Factor in Pregnant Women With Foetal Growth Restriction (VEGF in FGR)

Beni-Suef University

Status: Unknown

Conditions: Foetal Growth Restriction

Treatments: Other: serum Vascular Endothelial Growth Factor; Device: obstetric Ultrasound

Study type: Observational

Funder types: Other

Identifiers

NCT02245477

Beni-Suef 5

Details and patient eligibility

About

In this study we explore To explore the role of maternal serum vascular endothelial growth factor (VEGF) in pregnancies complicated by foetal growth restriction.

Full description

Small-for-gestational age (SGA) is defined as an estimated foetal weight (EFW) or abdominal circumference (AC) less than the 10th centileand severe SGA as an EFW or AC less than the 3rd centile. Foetal Growth Restriction refers to failure of the foetus to achieve its predetermined growth potential for various reasons.Foetus with foetal growth restriction (FGR) greatly contributes to perinatal mortality and short- and long-term morbidity. There is a 3-10 fold increase in perinatal mortality in pregnancies complicated by this FGR .The incidence of FGR in newborns ranges between 3 and 7% of the total population .FGR is thought to stem from placental hypoxia-induced vasoconstriction of the fetoplacental vessels, leading to placental hypoperfusion and thus fetal undernutrition. However, the effects of hypoxia on the fetoplacental vessels have been surprisingly little studied.Vascular endothelial growth factor (VEGF) is one of the factors that take part in placental angiogenesis. It is highly expressed during embryonic and foetal development..Angiogenesis involves the branching of new microvessles from pre-existing larger blood vessels.Angiogenesis plays a role in the development of the villous vasculature and the formation of terminal villi in human placenta. IUGR occurs as a result of the failure of elongation, branching and dilatation of the capillary loops and of terminal villous formation.

Enrollment: 100 estimated patients

Sex: Female

Ages: 20 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 20-40 years
• Gestational age 28-36 weeks
• Fetal growth restriction
• Patient consents to the procedure.
• BMI 20-30

Exclusion criteria

• Preeclampsia
• Diabetes Mellitus
• Fetal congenital anomalies

Trial design

100 participants in 2 patient groups

Obstetric Ultrasoud

Description:

Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.

Treatment:

Device: obstetric Ultrasound

Serum Vascular Endothelial Growth Factor

Description:

Serum VEGF concentration will be determined by Enzyme Linked immunosorbant assay using Quantitative Human VEGF Immunoassay kit (cat. No. DVEOO) manufactured by R \& D Systems, Inc , (Minneapolis, MN, USA).

Treatment:

Other: serum Vascular Endothelial Growth Factor